#Evolving Chronic Lymphocytic Leukemia Treatment The FDA Approval of BRUKINSAs Tablet Formulation

Zanubrutinib Tablets Greenlit by FDA for All Approved Indications

An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and Waldenström macroglobulinemia.

FDA Approves Zanubrutinib Tablet for All Indications

The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for patients with blood cancers.

#Evolving Chronic Lymphocytic Leukemia Treatment The FDA Approval of BRUKINSAs Tablet Formulation

In a groundbreaking development for oncology therapeutics, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235) announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA (zanubrutinib) for all five previously sanctioned indications. Originally introduced to combat chronic lymphocytic leukemia (CLL), this recent approval not only enhances the accessibility of this treatment modality but a…

FDA Approves Zanubrutinib Tablets in Multiple Hematologic Indications

Zanubrutinib tablets were found to have the same efficacy and safety as capsules based on 2 single-dose, open-label randomized phase 1 studies.

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.